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Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal 
cancers with very few available treatments. For many decades, gemcitabine was the 
only treatment for patients with PDAC. A recent attempt to improve patient survival by 
combining this chemotherapy with FOLFIRINOX and nab-paclitaxel failed and instead 
resulted in increased toxicity. Novel therapies are urgently required to improve PDAC 
patient survival. New treatments in other cancers such as melanoma, non-small-cell 
lung cancer, and renal cancer have emerged, based on immunotherapy targeting the 
immune checkpoints cytotoxic T-lymphocyte-associated antigen 4 or programmed 
death 1 ligand. However, the first clinical trials using such immune checkpoint inhibitors 
in PDAC have had limited success. Resistance to immunotherapy in PDAC remains 
unclear but could be due to tissue components (cancer-associated fibroblasts, desmo-
plasia, hypoxia) and to the imbalance between immunosuppressive and effector immune 
populations in the tumor microenvironment. In this review, we analyzed the presence of 
“good and bad immunological cops” in PDAC and discussed the significance of changes 
in their balance.
Keywords: pancreatic ductal adenocarcinoma, immune infiltrate, tumor microenvironment, immunosuppression, 
hypoxia, immune checkpoint
inTRODUCTiOn
Pancreatic ductal adenocarcinoma (PDAC) is the fourth-leading cause of cancer-related death in the 
world, with a 5-year survival rate of less than 5%. Each year more than 350,000 people worldwide 
are diagnosed and more than 340,000 die of the disease. The incidence is rising, and some reports 
project an over twofold increase in the number of new PDAC cases and PDAC deaths by 2030 (1).
The only curative treatment is complete surgical resection. Unfortunately, fewer than 20% of 
patients are candidates for surgery since their cancer has usually already spread before diagnosis. 
For this small subgroup of patients undergoing surgery, adjuvant treatment with the chemotherapy 
FiGURe 1 | Evolution of the immune cell population and pancreatic ductal adenocarcinoma (PDAC) development through the three Es of cancer immunoediting. 
During cancer immunosurveillance (1), immune effector cells M1 macrophages and N1 neutrophils are recruited to the tissue in order to eliminate heterogenic 
mutant/tumor cells. While these immune cells kill most tumor cells, specific resistant tumor clones (in dark blue) survive (2). An equilibrium between anti- and 
pro-tumor immune cells is maintained until tumor cells and immunosuppressive immune cells develop tumor escape mechanisms via the secretion of pro-tumor 
factors (IL-10, TGF-β, etc.) and inhibitory co-signaling molecules (3). Tumor escape induces the growth of tumor cells, angiogenesis, metastasis, the establishment 
of an immunosuppressive microenvironment with the presence of Tregs, tumor-associated macrophages (TAMs) such as M2, CAFs, myeloid-derived suppressive 
cells (MDSCs), tumor-associated neutrophils (TANs) such as N2 and with hypoxia and desmoplasia, which increase the pro-tumor impact and create a barrier (high 
blood pressure) against therapeutic drug delivery and recruitment of effector immune cells. M1: anti-tumor macrophages, M2: pro-tumor macrophages, N1: 
anti-tumor neutrophils, N2: pro-tumor neutrophils, CD8: CD8+ T cells, Th1/Th2: CD4+ Th1 (anti-tumor) or Th2 (pro-tumor) T cells, Treg: regulatory T cells, CAFs: 
cancer-associated fibroblasts.
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drug gemcitabine, Erlotinib, or more recently FOLFIRINOX has 
been shown to slightly improve survival (2, 3).
It appears that tumors develop multiple immunosuppres-
sive mechanisms to down-regulate the innate and effector 
arms of the immune system, thus compromising most of the 
immunotherapeutic strategies that have been proposed dur-
ing the last decade. In PDAC, the tumor microenvironment 
(TME) seems to play a pivotal role in tumor escape. A large 
number of cells or mechanisms participate together to improve 
the proliferation of tumor cells (4, 5). One of these is immune 
cells themselves, in particular immunosuppressive leukocytes 
that we will discuss in this review. Other components contrib-
ute toward PDAC cancerogenesis such as cancer-associated 
fibroblasts (CAFs) and extracellular matrix proteins. Together, 
these components interact with tumor cells to develop a 
pro-tumor environment and support proliferation. Another 
important mechanism called hypoxia exerts a strong impact 
on the structure of the tumor tissue (angiogenesis) and also on 
cells in the TME where hypoxia induces the development of 
immunosuppressive cell populations. Together these compo-
nents participate toward inducing the desmoplastic reaction 
in the TME, which increases the “sealing off ” (high level of 
intra-tumor blood vessel pressure) from effector immune cells 
(failing upon immune cell recruitment) and from drug delivery 
(chemoresistance) (6).
In this review, we focus on the organization and the role of 
infiltrating anti- or pro-tumor immune cell populations (referred 
to as “good and bad immunological cops,” respectively) during 
the course of PDAC and discuss the state-of-the-art of immuno-
therapy in PDAC.
inFLAMMATiOn AnD iMMUne CeLL 
inFiLTRATe in THe TMe
The link between tumor growth and inflammation has been 
greatly illustrated in the literature. The three Es (Elimination/
Equilibrium/Escape) of cancer immunoediting perfectly reflect 
the development of pancreatic cancer and the immune popula-
tion evolution in the TME (7). While inflammation is classically 
associated with an anti-tumor Th1 immune response (cancer 
immunosurveillance/elimination phase), tumor-associated 
inflammation is chronic, smoldering, and detrimental and 
participates toward tumor cell development and the accumula-
tion of immunosuppressive leukocytes (equilibrium and escape 
phases) (Figure 1). In some cancers such as PDAC, Kras or myc 
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oncogenes are responsible for such chronic and smoldering 
inflammation in the TME (8, 9). Regardless of origin, this inflam-
mation allows cancer cells to establish the tumor escape and 
development processes (10, 11). In PDAC, despite the hypoxia 
and hyaluronan-induced development of desmoplastic stroma, 
the TME is composed of several immune cell populations (12). 
At early stages, effector cells such as natural killer (NK) cells, 
CD8+ T  cells, and CD4+ T  cells can be present and activated. 
Nevertheless, during the selection of resistant tumor cells (dur-
ing the elimination process) and the development of the escape 
mechanism, the TME induces the recruitment of monocytes and 
neutrophils, which then have acquired an anti-inflammatory 
phenotype (M2 and N2 respectively), the recruitment of 
myeloid-derived suppressive cells (MDSCs), the recruitment 
and/or the polarization of regulatory T cells (Tregs) or Th17, and 
the recruitment of Th1 to Th2 cell shift (13, 14). Furthermore, 
CD8+ T  cells, NK  cells, and dendritic cells are deactivated or 
exhausted in order to inhibit anti-tumor function. Of course, 
the transformation of pro-inflammatory to anti-inflammatory 
in the TME increases the tumor growth and angiogenesis and 
correlates with poor survival (Figures 1 and 2) (13).
GOOD COPS
effector immune Cells
CD8+ T Cells
Tumor infiltrated CD8+ T cells (also called cytotoxic T lympho-
cytes; CTLs) are immune effector cells that can kill cancer cells 
using perforin and granzyme molecules. Analysis in peripheral 
blood has revealed significantly decreased circulating CTLs and 
lower perforin expression levels in pancreatic cancer patients 
compared with healthy controls (15). Immunohistochemistry on 
pancreatic cancer samples showed a higher cellular infiltration 
compared to normal pancreas and survival studies have shown 
that higher levels of tumor infiltrating CD4+ and CD8+ T cells are 
associated with longer survival (16).
Shortly after T-cell activation, cytotoxic T-lymphocyte-
associated antigen 4 (CTLA4) is translocated to the plasma 
membrane. This co-receptor molecule binds to B7 ligand with a 
higher affinity than does the co-receptor CD28, leading to inhi-
bition of the T-cell activation. Furthermore, PDAC cells express 
PD-L1, which binds to PD1 expressed on activated T cells (17). 
Interaction between these molecules leads to T-cell anergy or 
death and consequently promotes tumor progression (18).
The restoration of exhausted CD8+ T  cells and recovery of 
their effector role represent one of the main therapeutic objectives 
toward the destruction of cancer cells.
CD4+ T Cells
CD4+ T cells (T helper cells) play an important role in the immune 
response by secreting several cytokines that modulate the function 
of B and CD8+ T cells. Their peripheral blood levels are reduced 
in patients with pancreatic cancer compared to healthy controls 
(19). Naive CD4+ T cells can differentiate into the following two 
main subsets: Th1  cells, which support cell-mediated immune 
responses by secreting IL-2 and IFN-γ (activate macrophages and 
CD8+ T-cell proliferation), and Th2 cells, which induce humoral 
immune responses by secreting IL-4, IL-5, IL-6, IL-9, IL-10, and 
IL-13 (stimulate B-cell proliferation and induce B-cell antibody 
class switching) (20). In PDAC cancer, the shift from Th1 to Th2 
cells is correlated to reduced survival.
NK Cells
Natural killer cells are cytotoxic lymphocytes of the innate 
immune system. Activation of these cells is determined by the 
balance between activating and inhibitory receptor stimulation. 
Analysis of peripheral blood mononuclear cells has revealed 
reduced levels of NK cells in patients with PDAC compared to 
healthy controls (19). Patients were also found to have signifi-
cantly lower levels of two activating receptors (CD226 and CD96) 
on their circulating NK cells compared to healthy controls (21). 
The decrease in the level of activating receptors on NK cells could 
indicate dysfunction of these cells and may represent a factor pro-
moting PDAC progression. These data suggest that reactivation 
of NK cells via these activator receptors could be a new target for 
cancer immunotherapy.
BAD COPS
Anti-inflammatory Myeloid Cells
Tumor-Associated Macrophages (TAMs)
Monocytes recruited to the tumor site can differentiate into 
TAMs. In the majority of solid tumors such as in PDAC, 
TAMs represent the most abundant immune population in 
the TME. Tumor cells express many factors including CCL2 
(under hypoxic conditions), M-CSF or GM-CSF, IL-10, TGF-β, 
and IL-6, all of which favor the recruitment and generation 
of TAMs (22). At early cancer stages, TAMs can be polarized 
into an anti- (M1) or pro- (M2) tumor phenotype (23, 24), 
whereas at advanced stages, they are mainly present as the M2 
subtype (CD14+ CD163+) (23) and their presence is associated 
with bad prognosis in PDAC (25, 26). As reported by Cui et al, 
TAMs play large roles in the promotion of tumor growth and 
development of an immunosuppressive microenvironment. 
They do this by secreting angiogenic factors (IL-6, VEGF, and 
MMP), as well as immunosuppressive factors (IL-10 TGF-β), 
that promote the generation of an immunosuppressive cell 
population and inhibit effector T cells, and also other factors 
such as chemokines and cytokines that promote metastasis 
and epithelial–mesenchymal transition (27). Therefore, TAMs 
represent an important therapeutic target for inhibition at the 
level of their activation, recruitment, and survival or for the 
reprogramming of polarization (27, 28). Shibuya et al. showed 
that multimodal neoadjuvant chemotherapy could decrease 
the number of immunosuppressive infiltration cells such as 
myeloid cells (29).
Tumor-Associated Neutrophils (TANs)
Analogous to the M1 and M2 dichotomy for TAMs, TANs exhibit 
a pro-tumor N2 profile with pro-tumor function through the 
influence of TGF-β (30). Furthermore, pancreatic cancer cells 
attract neutrophils through the secretion of chemokines, such 
FiGURe 2 | Pancreatic ductal adenocarcinoma (PDAC) development induces the shift of pro-inflammatory to immunosuppressive immune populations. At early 
PDAC stages, a primarily anti-tumor immune population favors the effector T-cell functions of such as CD8+ and natural killer (NK) cells toward the prevention of 
tumor cell growth. Despite this initial anti-tumor response, over time chronic activation of these effector immune cells brings about a smoldering inflammation 
process that selects resistant tumor clones resulting in the promotion and development of immunosuppressive immune populations under hypoxic stress.
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as CXCL8 and CXCL16 (31). Few studies have evaluated the 
function of TANs; however, those with the N2 profile have 
been shown to produce matrix metallopeptidases including 
MMP-8, MMP-9, neutrophil elastase, reactive oxygen species 
(ROS), and VEGF and some inflammatory cytokines including 
TNFα and GM-CSF, which promote tumor and immune cell 
proliferation (metastatic potential) and favor chronic inflam-
mation (31, 32).
Myeloid-Derived Suppressor Cells
Myeloid-derived suppressor cells are a population of cells defined 
by their immature state, myeloid origin and capacity to suppress 
the immune response. Through factors in the TME, they can 
acquire phenotypic and functional characteristics of TAMs and 
TANs and are thus called mononuclear (Mo-) or granulocytic 
(G-) MDSCs (14, 31). They are strongly immunosuppressive by 
their ability to inhibit T-cell proliferation, IFNγ production, and 
effector T-cell function and to favor Treg generation through the 
secretion of ROS, Arg1, and iNOS (33, 34). They also promote 
tumor growth by VEGF and MMP9 secretions. High concentra-
tion of MDSCs in the peripheral blood is associated with poor 
prognosis in PDAC (35).
Mast Cells (MCs)
Mast cells can release cytotoxic granules and have the capacity 
to recruit other immune cell populations by chemokine secre-
tion. They have been found in significantly higher numbers 
in PDAC compared to those in normal pancreatic tissue (36), 
where they support tumor growth and angiogenesis and inhibit 
anti-tumor immunity. The MCs accumulate within the TME, 
along with macrophages, through the action of tumor-derived 
chemoattractants such as MCP-1 and RANTE and by tumor-
secreted VEGF and FGF (37). MC accumulation correlates 
with higher tumor grade, diminished survival, and lymph node 
metastasis.
In vitro, MCs induce PDAC cell proliferation and migration 
(angiogenesis and metastasis) by secreting factors including 
secretin, VEGF, and IL-8 and tumor growth factors including 
PDGF and proteases (38, 39).
Anti-inflammatory Lymphoid Cells
Tregs
In PDAC and solid tumors, CD4+ CD25+ Foxp3+ Tregs are 
strongly associated with poor prognosis and inversely correlated 
to the presence of CD8+ T  cells, with more advanced disease 
presentation, a lower chance of surgical resection and a poorer 
survival after resection (36, 40). Patients with PDAC have 
increased numbers of Tregs. They produce IL-10 and TGF-β and 
express CTLA-4; thus, they inhibit effector T cells and induce M2 
profile TAMs and N2 profile TANs (41).
Th17 Lymphocytes
The role of Th17  cells in cancer is highly controversial. Their 
function seems to depend on the type of cancer, the tumor stage, 
and the localization (42). In PDAC, while some evidence favors 
a higher level of Th17 cells in advanced stage tumors, other data 
in a murine model of pancreatic cancer support Th17 induction 
increasing survival (43, 44). This inconsistency can be explained 
by the plasticity of Th17 cells and their ability to promote smold-
ering inflammation at early stages (45–47). Indeed, Th17  cells 
are polarized on the one hand by IL-6, IL-23, and Il-1β with 
pro-inflammatory functions (impact on smoldering inflamma-
tion and recruitment of inflammatory immune population) and 
on the other hand by TGF-β, which induces anti-inflammatory 
functions (impact on tumor growth, immunosuppressive 
microenvironment, and angiogenesis) (46, 48). Furthermore, the 
shift of Th17 to Treg, explained by the plasticity of these cells, is 
important. In PDAC, patients were shown to exhibit Th17/Treg 
disorders with higher Treg and lower Th17 cells (49).
Th2 Lymphocytes
Th2 cells (GATA-3+ IL-13+ IL-4+), in contrast to Th1  cells, are 
anti-inflammatory T cells. In PDAC, the TME and CAFs were 
shown to induce the polarization of Th2 cells by IL-13-mediated 
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dendritic cell secretion in vitro (50). The Th2 cells produce IL-13 
and IL-4 and thereby induce M2 macrophages or TAMs, which 
further increases the anti-inflammatory TME. Furthermore, 
via an amplification loop and T-cell plasticity, Th2 cells inhibit 
Th1-cell polarization and induce themselves. In tumor tissue, 
Th2 T-cell infiltrates are a predictive marker of poor prognosis, 
confirmed by the shift of Th1 to Th2 cells within the TME (13).
ɣδ T Cells
ɣδ T cells are “unconventional” T cells. Unlike αβ T cells, these 
lymphocytes do not require antigen processing and major 
histocompatibility complex presentation of peptide epitopes. In 
contrast to current dogma, one study using a mouse model and 
human samples showed that ɣδ T cells have no anti-cancer prop-
erties in pancreatic cancer (51). In vivo deletion of ɣδ T cells using 
a neutralizing antibody resulted in a robust protection against 
oncogenic progression. The analysis also revealed that infiltrating 
ɣδ T cells express high levels of T-cell exhaustion ligands (PD-L1 
and Galectin-9) and may block the immune response by immune 
checkpoint inhibition. Altogether these data suggest that, in 
PDAC, ɣδ T cells promote pancreatic oncogenesis and that their 
deletion or reactivation could be a novel therapeutic strategy. 
Surprisingly, the key regulator of Vγ9Vδ2 function BTN3A1 
was found to act as a critical marker of PDAC prognosis and is 
detectable either by IHC or by its soluble receptor sBTN3A1 (52).
Other Main Anti-inflammatory 
Mechanisms
Hypoxia
Pancreatic cancer stroma is composed of several main compo-
nents: CAFs, immune cells and associated cytokines, adipocytes, 
and endothelial cells. These stromal components are involved in 
the production of highly toxic conditions including low pH and 
low oxygen environment (hypoxia). To define the hypoxic status 
of pancreatic cancer, one study measured tissue oxygenation of 
the tumor and normal adjacent pancreas during pancreaticoduo-
denectomy surgery (53). Results of this study showed that PDAC 
are highly hypoxic compared to normal pancreas.
Cancer cells under hypoxic conditions are more resistant to 
radiation and chemotherapy (54, 55). This ability to survive is 
mainly conferred by the hypoxia-inducible pathway involving 
transcription factors able to induce the expression of several genes 
controlling cell survival, glycolysis, and other cellular metabolism 
events. Recent evidence supports the hypothesis of hypoxia being 
one cause of radioresistance. Indeed, Hajj et al. showed that radia-
tion therapy in combination with TH-302 (a hypoxia-activated 
pro-drug) allowed tumor growth delay in an orthotopic model 
of PDAC by comparison with the outcome following these two 
treatments given separately (56). This TH-302 compound is cur-
rently being tested in a pancreatic cancer Phase I clinical trial in 
combination with Nab-paclitaxel and gemcitabine.
Despite the high levels of hypoxia found in pancreatic can-
cer, which would be expected to promote angiogenesis, PDAC 
remains poorly vascularized. This poor vascularization limits 
blood flow to the tumor and is associated with prominent des-
moplasia, which prevents drug delivery and could impede the 
immune response (57). This hypoxia seems to impact on several 
escape mechanisms and could therefore be a relevant target for 
next generation therapeutic options.
Pancreatic Stellate Cells (PSCs)
In non-inflamed pancreas, PSCs are resident cells involved 
in maintaining tissue homeostasis by regulating extracellular 
matrix turnover (58). During pancreatic injury, quiescent PSCs 
are activated and transform into myofibroblast-like cells. These 
activated PSCs secrete extracellular matrix proteins, which gener-
ate fibrosis and limit drug delivery to cancer cells (59). Inordinate 
secretion of extracellular matrix proteins is also linked to hypoxia 
(see paragraph above) and promotes cancer cell proliferation.
Pancreatic stellate cells can also modulate immune cells via 
their secretion of cytokines. Indeed, secretion of CXCL12 by 
activated PSCs reduces the migration of CD8+ and CD4+ T cells, 
NK  cells, and Tregs to the juxtatumoral compartment within 
close proximity to the tumor (60). Another study showed that 
PSCs secreted Galectin-1, which mediated immunosuppression 
of CD8+ T  cells and promoted T-cell apoptosis (61). All these 
data suggest that PSCs could be a good target to enhance immu-
notherapy for PDAC.
iMMUnOTHeRAPY in PDAC:  
STATe-OF-THe-ART
Pancreatic ductal adenocarcinoma is currently recognized as one 
of the deadliest human malignancies. Compared to other cancers, 
PDAC shows marked resistance to conventional forms of chemo-
therapy and often develops without early symptoms making its 
detection and early diagnosis very difficult, greatly limiting treat-
ment capability. No current treatment option has demonstrated 
long-term benefit in patients with advanced disease who are not 
eligible for surgery, which represents the majority (80%) of PDAC 
cases. Although some risk factors have been identified (such as 
tobacco use, family history of PDAC, and a personal history of 
pancreatitis, diabetes, or obesity), few patients diagnosed with 
PDAC have identifiable risk factors (1, 62). For many years, gem-
citabine monotherapy was the only treatment available for this 
cancer (2). More recently, studies found that using gemcitabine 
in combination with FOLFIRINOX and nab-paclitaxel was more 
effective than gemcitabine monotherapy (3). Unfortunately, this 
combination therapy prolonged survival by only a few months 
and actually increased toxicity.
New therapies are thus urgently needed to combat this highly 
lethal cancer and further extend the lives of affected patients. 
Immune-based strategies to treat various cancers during the 
early stages of development, as well as new immunological 
approaches to treat advanced disease, are showing significant 
promise where other approaches have failed (63, 64). In PDAC, 
potential immunology-based therapies have provided new hope 
and can be divided into three main subtypes: (i) therapeutic vac-
cines aimed, as those protecting against infection, to stimulate 
the immune system to produce tumor-specific T cells and B cells 
(65); (ii) adoptive therapy in which ex vivo expanded cytotoxic 
cells are injected into the tumor to kill cancer cells (66); and (iii) 
6Foucher et al. Immune Cell Impact in PDAC
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immune checkpoint inhibitors. After their activation, T  cells 
express “blocker” molecules called immune checkpoints, which 
allow them to return to normal. Cancer cells divert this block-
ing mechanism by expressing ligands of immune checkpoint 
resulting in T-cell anergy. New treatments based on monoclonal 
therapy have been established to counteract T-cell inhibition 
by immune checkpoint. Antibodies targeting CTLA4, PD1, 
and programmed death 1 ligand (PDL1) have demonstrated 
significant efficacy in non-small-cell lung cancer, renal cancer, 
and melanoma (67).
Unfortunately, immune checkpoint inhibitor monotherapy 
targeting these three molecules appears to be ineffective in 
PDAC (68). One explanation for this resistance could be found 
in the composition of the immune cell infiltrate. As discussed 
earlier, several cell subtypes found in the PDAC TME have potent 
immunosuppressive functions. MDSCs promote pro-tumor mac-
rophages, decrease cytotoxic T cells, and recruit Treg lymphocytes. 
TAMs inhibit T-cell function and secrete immunosuppressive 
factors (69). Treg lymphocytes secrete immunosuppressive 
cytokines (IL-10 and TGF-β) and limit CD8+ T-cell activation by 
the consumption of IL2 available by IL2Rα (70). Together, these 
cells generate an immunosuppressive environment, which likely 
interferes with immune checkpoint inhibitors.
Another reason that could explain the immune-based therapy 
inefficiency is the desmoplastic feature of PDAC stroma caused 
by hypoxia and TME components, as discussed earlier. Novel 
therapies targeting these two last obstacles are urgently needed 
which, when combined with immune checkpoint inhibitors, are 
expected to provide substantial benefits to patients with PDAC. 
Furthermore, CTLA4, PD1, and PDL1 may not be the major 
immune checkpoint molecules involved in immune system inhi-
bition in PDAC. A complete analysis of the immune checkpoint 
molecules expressed by cancer cells in PDAC could help decipher 
how immune system inhibition is set up and thus reveal new 
targets.
Finally, the biology and genetics in PDAC also appear to be 
very important (11, 71). Indeed, several genetic and transcrip-
tomic studies have demonstrated the classification of PDAC into 
two or more subtypes including basal versus classic or immuno-
genic versus non-immunogenic (72). Chen and Mellman recently 
described cancer-immune phenotyping into the following three 
different subtypes: the immune-desert, the immune-excluded, 
and the inflamed tumor (73).
Future immunotherapies should now consider such pheno-
typing in order to adapt therapeutic strategies to specific groups 
of patients with the aim of increasing patient survival.
COnCLUSiOn
In PDAC and most solid tumors, the TME and, in particular, the 
immune network play a pivotal role in their development. From 
the elimination phase where effector immune cells eliminate 
and select specific resistant tumor cells to the equilibrium and 
escape phases, tumor cells induce an immunosuppressive TME. 
These may be found to target myeloid cells and Tregs, as the most 
abundant cells in the TME of PDAC. PDAC is a devastating dis-
ease that is mostly diagnosed at advanced stages at which strong 
immunosuppressive immune populations and desmoplastic 
environment have already developed, likely explaining the inef-
ficiency of current immunotherapies in this cancer. The relation 
between the PDAC’s biology, genetic, and immune network seems 
to be very closed and important to adapt therapy for each patient. 
That is why, further studies are needed to better understand the 
escape mechanisms relating to immunosuppression in order to 
reveal the best immune checkpoint therapeutic strategies.
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